Compare NVNI & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NVNI | IXHL |
|---|---|---|
| Founded | 2019 | 2001 |
| Country | Brazil | Australia |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.2M | 49.1M |
| IPO Year | N/A | N/A |
| Metric | NVNI | IXHL |
|---|---|---|
| Price | $3.55 | $0.44 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 150.9K | ★ 23.6M |
| Earning Date | 09-30-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $31,250,627.00 | $12,000.00 |
| Revenue This Year | $12.05 | N/A |
| Revenue Next Year | $15.02 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1491.58 | N/A |
| 52 Week Low | $1.44 | $0.08 |
| 52 Week High | $121.90 | $2.25 |
| Indicator | NVNI | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 56.74 | 59.25 |
| Support Level | $2.80 | $0.35 |
| Resistance Level | $3.00 | $0.50 |
| Average True Range (ATR) | 0.31 | 0.03 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 53.42 | 69.19 |
Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.